Protein-tyrosine phosphatases (PTPs) are important for the control of proper cellular tyrosine phosphorylation. Despite the large number of PTPs encoded in the human genome and the emerging roles played by PTPs in human diseases, a detailed understanding of the role played by PTPs in normal physiology and in pathogenic conditions has been hampered by the absence of PTPspecific inhibitors. Such inhibitors could serve as useful tools for determining the physiological functions of PTPs and may constitute valuable therapeutics in the treatment of several human diseases. However, because of the highly conserved nature of the active site, it has been difficult to develop selective PTP inhibitors. By taking an approach to tether together two small ligands that can interact simultaneously with the active site and a unique proximal noncatalytic site, we have recently acquired Compound 2 (see Fig. 1 ), the most potent and selective PTP1B inhibitor identified to date, which exhibits several orders of magnitude selectivity in favor of PTP1B against a panel of PTPs. We describe an evaluation of the interaction between 2 and its analogs with PTP1B and its site-directed mutants selected based on hydrogen/deuterium exchange of PTP1B backbone amides in the presence and absence of 2. We have established the binding mode of Compound 2 and identified 12 PTP1B residues that are important for the potency and selectivity of Compound 2. Although many of the residues important for Compound 2 binding are not unique to PTP1B, the combinations of all contact residues differ between PTP isozymes, which suggest that the binding surface defined by these residues in individual PTPs determines inhibitor selectivity. Our results provide structural information toward understanding of the molecular basis for potent and selective PTP1B inhibition and further establish the feasibility of acquiring potent, yet highly selective, PTP inhibitory agents.
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Protein-tyrosine phosphatases (PTPs) 1 are a large and structurally diverse family of signaling enzymes that, together with protein-tyrosine kinases, modulate the cellular level of proteintyrosine phosphorylation. An appropriate level of tyrosine phosphorylation is essential for regulating cell growth, differentiation, metabolism, progression through the cell cycle, cellcell communication, cell migration, gene transcription, ion channel activity, the immune response, and apoptosis/survival decisions (1) . As observed with protein-tyrosine kinases, defective or inappropriate regulation of PTP activity leads to aberrant tyrosine phosphorylation, which contributes to the development of many human diseases including cancers and diabetes (2) . The hallmark that defines the PTP superfamily is the active site amino acid sequence (H/V)CX 5 R(S/T), also known as the PTP signature motif, in the catalytic domain. Based on this unique structural feature, it is estimated that more than 100 PTPs are encoded in the human genome (3) .
Biochemical and structural studies have shown that all PTPs share a common mechanism of action and catalyze the same reaction, namely the hydrolysis of phosphotyrosine (4). However, the cellular processes in which the PTPs are involved can be both highly specialized and fundamentally important. Despite the large number of PTPs identified to date and the emerging roles played by PTPs in human diseases, a detailed understanding of the role played by PTPs in normal physiology and in pathogenic conditions has been hampered by the absence of PTP-specific inhibitors. Such specific small molecule inhibitors could serve as useful tools for determining the physiological functions of PTPs and may constitute valuable therapeutics in the treatment of several human diseases.
There is intense interest in obtaining specific and potent PTP inhibitors for biological studies and pharmacological development (4, 5) . However, there have been relatively few reports on potent and selective PTP inhibitors. An important issue that needs to be resolved is, given the highly conserved nature of the PTP active site, whether selectivity can be achieved in PTP inhibitor development. We believe that it is feasible to acquire potent and highly selective PTP inhibitory agents. This belief was prompted by previous findings that pTyr alone is not sufficient for high affinity binding to PTPs and that amino acid residues flanking the pTyr furnish additional interactions for efficient and high affinity PTP substrate recognition (6 -11) . These results indicate that there are subpockets adjacent to the PTP active site that can also be targeted for inhibitor development. These studies, together with the discovery of a second aryl phosphate binding site adjacent to the active site in PTP1B (12) provide a molecular basis for addressing and manipulating PTP inhibitor potency and specificity and suggest a novel paradigm for the design of potent and specific PTP inhibitors, namely bidentate ligands that bind to both the active site and a unique adjacent peripheral site. Consequently, unique PTP subpockets that border the active site may be targeted to enhance inhibitor affinity and selectivity. The rationale for the enhanced affinity of bidentate inhibitors is based on the principle of additivity of free energy of binding. The interaction of an inhibitor with two independent sites (e.g. pTyr site and a unique peripheral site) in one PTP would be expected to confer exquisite specificity, because other PTPs may not possess an identical second site interaction.
To identify bidentate inhibitors capable of simultaneously occupying both the active site and a unique peripheral site in PTP1B, we have employed a combinatorial library/high throughput screening approach that lead to the identification of Compound 2 (see Fig. 1 ), which displays a K i value of 2.4 nM for PTP1B and exhibits several orders of magnitude selectivity in favor of PTP1B against a panel of PTPs (13) . Compound 2 is the most potent and selective PTP1B inhibitor identified to date. This result serves as a proof-of-concept in PTP inhibitor development, as it demonstrates the feasibility of acquiring potent, yet highly selective, PTP inhibitory agents.
Although we have demonstrated that it is possible to obtain potent and selective PTP1B inhibitors, it is not clear why Compound 2 is so specific for PTP1B. To unravel the structural basis of PTP1B-inhibitor specificity, and to lay the groundwork for future design of more potent and specific compounds that can interfere with the processes that are controlled by PTP1B, we must first identify the regions that form the inhibitor binding sites. The present study was initiated to assess the exact binding mode between Compound 2 and PTP1B, using hydrogen/deuterium exchange in combination with electrospray ionization mass spectrometry, site-directed mutagenesis, and kinetic analysis. The results provide insights into the molecular basis of the potency and selectivity of Compound 2 for PTP1B. The increased understanding of PTP1B-inhibitor recognition may also stimulate efforts to design specific inhibitors "tailored" to other members of the PTP family.
EXPERIMENTAL PROCEDURES
Materials-p-Nitrophenyl phosphate (pNPP) was purchased from Fluke Co. The procedure for the preparation of the stock solution of sodium orthovanadate has been described previously (9) . Pepsin was obtained from Worthington Biochemical Co. (Freehold, NJ), and D 2 O (99.9 atom % D) was from Isotec Inc. (Miamisburg, OH). All other chemicals and reagents were of the highest grade available commercially.
Site-directed Mutagenesis-All mutant forms of PTP1B were generated using the QuickChange kit from Stratagene. The oligonucleotide primers used for mutagenesis were from Sigma. All of the mutations were confirmed by DNA sequencing.
Protein Purification-PTP1B was expressed in Escherichia coli and purified to homogeneity as described previously (12) . The PTP1B/N40A and PTP1B/N44A transformed cells were grown for 12 h at room temperature after isopropyl-1-thio-␤-D-galactopyranoside induction. All mutant forms except R47A and R47E were purified similarly to wildtype PTP1B. R47A and R47E were purified using a procedure described previously (14) . Protein purity was checked by 12% SDS-PAGE, which showed a single band at 37 kDa. The protein concentration was determined from absorbance measurement at 280 nm using an absorbance coefficient of A 1 mg/ml 280 ϭ 1.24. Determination of Kinetic Constants Using pNPP as a Substrate-PTP activity was assayed at 30°C in a reaction mixture (0.2 ml) containing pNPP concentrations ranging from 0.2 to 5 K m . The following buffered solution was used for activity measurements: at pH 7.0, 50 mM 3,3-dimethylglutarate, 1 mM EDTA, and the ionic strength of 0.15 M, adjusted by addition of NaCl. Initial rate measurements for the enzyme-catalyzed hydrolysis of pNPP were conducted as described previously (15) . The steady state kinetic parameters were determined from a direct fit of the data to the Michaelis-Menten equation using the nonlinear regression program KINETASYST (IntelliKinetics, State College, PA).
Determination of Kinetic Constants Using pTyr-containing Peptides
as Substrates-PTP1B-catalyzed hydrolysis of pTyr-containing peptides was continuously monitored at 282 nm using a PerkinElmer Life Sciences Lambda 14 spectrophotometer (16). The instrument was equipped with a water-jacketed cell holder, permitting maintenance of the reaction mixture at the desired temperature. The enzyme assays were conducted at 30°C. When K m Ͻ Ͻ [S], both k cat and K m values can be determined using the integrated Michaelis-Menten equation (16) shown in Equation 1 .
The reaction mixture (0.6ml) contained 100 M substrate in 50 mM 3,3-dimethylglutarate, pH 7.0, 1 mM EDTA, 1 mM dithiothreitol with an ionic strength of 0.15 M (adjusted with NaCl). The reaction was initiated by addition of PTP1B at a final concentration in the range of 7 to 1800 nM PTP1B. The data were analyzed using a nonlinear least squares regression program (KaleidaGraph; Synergy Software).
Inhibition Studies-Inhibition constants were determined for the wild-type PTP1B and the mutants in the following manner. At various fixed concentrations of the inhibitor, the initial rate at various pNPP concentrations was measured by following the production of p-nitrophenol as described above. All experiments were performed at 30°C in 50 mM 3,3-dimethylglutarate buffer, pH 7.0, containing 1 mM EDTA with an ionic strength of 0.15 M adjusted with NaCl. EDTA was excluded from the buffer for measurements with vanadate as an inhibitor. The inhibition constant and inhibition pattern were evaluated using the direct curve-fitting program KINETASYST (IntelliKinetics) to the appropriate equations.
Hydrogen/Deuterium Exchange Studies Followed by Mass Spectrometry Analysis-The complex of PTP1B with Compound 2 was formed by incubating 320 M PTP1B with 1 mM inhibitor in 50 mM 3,3-dimethylglutarate H 2 O buffer, pH 7.0, ionic strength 0.15 M (adjusted with NaCl), for at least 1 h at 4°C. Hydrogen/deuterium (H/D) exchange was initiated by adding 1 l of a 320 M PTP1B or PTP1B-inhibitor complex solution to 19 l of 50 mM 3,3-dimethylglutarate buffer in 99.9 atom % D 2 O, pD 7.0, ionic strength 0.15 M (adjusted with sodium chloride). The resulting H/D exchange solutions were maintained at 25°C using a water bath and allowed for exchange for different periods of time. At appropriate intervals, H/D exchange reaction was quenched by the addition of an equal volume of cold 0.5 M phosphate buffer, pH 2.5, in the absence or presence of 20 M pepsin. Pepsin digestion was performed at 0°C for 4 min. Deuterated protein solution or pepsin digest was loaded immediately onto a Vydac 1.0 ϫ 50-mm C 4 or C 8 column, respectively. A Shimadzu HPLC equipped with two LC-10AD pumps was used to generate an acetonitrile gradient. Solvent A was 94.95% H 2 O containing 5% acetonitrile and 0.05% trifluoroacetic acid, and Solvent B was 95% acetonitrile containing 4.95% H 2 O and 0.05% trifluoroacetic acid. A low volume static mixing tee was used to minimize the delay period for HPLC. The solvent precooling coil, static mixing tee, Rheodyne injector, and column were immersed in an ice bath (0°C) to minimize back exchange with HPLC solvents. Desalted at 5% solvent B for 5 min, the protein eluted at ϳ1.7 min with a 2-min 5-95% B gradient, and the peptic peptides eluted between 2.2 and 7.4 min with a 0.5-min 5-15% B gradient followed by an 8-min 15-45% B gradient. The column effluent (50 l/min) was delivered directly to a ThermoQuest (Riviera Beach, FL) LCQ quadrupole ion trap mass spectrometer for mass analyses of deuterated protein and its peptic peptides. MagTran 1.0 software (written by Dr. Zhongqi Zhang) was used to determine the centroid value for each peak in the list processed from the mass spectrum. To identify the sequences of peptic peptides, tandem mass spectrometry was performed on HPLC fractions of the peptic digest collected at 30-s intervals. The extent of deuterium exchange was calculated using Equation 2 (17),
where m is the measured mass of deuterated protein or peptide, m 0% is the measured mass of a "zero-deuteration" control prepared by adding 1 l of 320 M protein solution into a 19:20 (v/v) mixture of deuterated buffer and quenching buffer, m 100% is the measured mass of a "full-deuteration" control prepared by incubating a deuterated protein sample for 5 h at 60°C followed by addition of an equal volume of cold quenching buffer, and H is the total exchangeable amide hydrogens.
General Procedures for Chemical Synthesis-All moisture-sensitive reactions were carried out in oven-dried glassware under a positive pressure of dry N 2 or Ar. 2-(1H-Benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), Fmoc-amino acids, N-hydroxybenzotriazole, N-methylmorpholine, piperidine, Rink amide resin, and triisopropylsilane for solid-phase synthesis were purchased from Advanced ChemTech. Cesium carbonate, cuprous bromide, benzyl bromide, diethyl bromodifluorophosphonate, dry N,N-dimethylacetamide (DMA), dry N,N-dimethylformamide (DMF), iodotrimethylsilane, NMR solvents, and zinc powder were purchased from Aldrich. HPLC-grade solvents acetonitrile, DMF, ethyl acetate, ethyl ether, and methylene chloride were purchased from Fisher Scientific. 4-Iodophenylacetic acid was purchased from Lancaster Synthesis. New compounds were characterized by 1 H NMR (300 MHz), 13 C NMR (75.5 MHz), 19 F NMR (282 MHz), and 31 P NMR (121 MHz) at 299 K and by electron spray ionization (ESI) or matrix-assisted laser desorption ionization-time of flight mass spectrometry (MS).
Synthesis of Benzyl 4-[(Diethylphosphono)difluoromethyl]phenylacetate-
The compound was synthesized by using either (diethylamino)-sulfur trifluoride as described previously (13) or the following modified procedure: to a mixture of 4-iodophenylacetic acid (360 mg, 1.4 mmol), Cs 2 CO 3 (500 mg, 1.5 mmol), and benzyl bromide (260 mg, 1.5 mmol) was added dry DMF (5 ml), and the suspension was stirred at room temperature overnight before it was filtered. The filtrate was subjected to CH 2 Cl 2 /water extraction, and the organic portion was concentrated and flash column-purified to furnish 420 mg (87% yield) of benzyl 4-iodophenylacetate ( 1 H 41) . Zinc powder (260 mg, 4 mmol) in DMA (3 ml) was sonicated for 1 h prior to treatment with a solution of diethyl bromodifluorophosphonate (13, 18) (0.75 ml, 4.2 mmol) in DMA (2 ml). Sonication was continued for an additional 3 h, and then cuprous bromide (0.65 g, 4.5 mmol) was added in one portion. After 30 min a DMA solution (2 ml) of benzyl 4-iodophenylacetate (358 mg, 1 mmol) was added dropwise, and the resulting mixture was stirred for 24 h, diluted with ethyl acetate, washed with water and brine, dried over sodium sulfate, and filtered, and the solvent was removed via rotary evaporation. Flash column chromatography afforded the desired product benzyl 4-[(diethylphosphono)difluoromethyl]-phenylacetate (277 mg, 66%), as confirmed by NMR (13) .
Solid-Phase Synthesis of Compounds 1-4-Synthesis was performed on Rink amide resin using a standard protocol for HBTU/N-hydroxybenzotriazole/N-methylmorpholine activation of carboxylic acids. The coupling reaction was performed in DMF for 1.5 h using a 3-fold excess of acid relative to resin-bound amine. Fmoc-O-phospho-L-tyrosine or Fmoc-4-phosphonodifluoromethyl-L-phenyalanine with an unprotected side chain, Fmoc-L-aspartic acid with a tert-butyl protected side chain, and 4-phosphophenylacetic acid (13) or 4-phosphonodifluoromethylphenylacetic acid were used as appropriate. Fmoc-4-phosphonodifluoromethyl-L-phenylalanine ( 1 H NMR (300 MHz, Me 2 SO) ␦ 7.2-7.9 (m, 12H), 4.2 (m, 4H), 3.1 (dd, J ϭ 3.8, 14 Hz, 1H), 2.9 (dd, J ϭ 11, 14 Hz, 1H); 31 P NMR (121.5 MHz, Me 2 SO) ␦ 4.3 (t, J ϭ 108 Hz)) and 4-phosphonodifluoromethylphenylacetic acid (13) were obtained, respectively, by treatment of their ethyl-protected phosphonate esters with iodotrimethylsilane (19, 20) . Fmoc removal was effected with 20% piperidine in DMF. Final cleavage and side chain deprotection was achieved by treatment with a mixture of 2.5% triisopropylsilane, 2.5% water, and 95% trifluoroacetic acid at room temperature for 2.5 h. The resin was removed by filtration, and the remaining solution was concentrated. The residue was triturated with ether, dissolved in water, and purified by semi-preparative reverse phase HPLC (0.1% trifluoroacetic acid in water and acetonitrile) to afford the desired compounds. The NMR and MS data for Compounds 1 and 2 were described (13). 
RESULTS AND DISCUSSION
Most of previous work on PTP inhibitor development has been focused on PTP1B (4). PTP1B is considered as a negative regulator of the insulin-stimulated signal transduction pathway (21-23). Mice lacking functional PTP1B exhibit increased sensitivity toward insulin in skeletal muscle and liver and are resistant to obesity (24, 25) . These observations suggest that specific PTP1B inhibitors may enhance insulin sensitivity and act as effective therapeutics for the treatment of Type II diabetes, insulin resistance, and obesity. However, in addition to a role in insulin signaling, PTP1B is also implicated in several other physiological and pathological processes including transformation by Neu oncogene (26), activation of Src kinases (27) , antagonizing signaling by the epidermal growth factor receptor (28, 29) and the oncoprotein p210 bcr-abl (30) , and negative regulation of integrin signaling by binding and dephosphorylating ␤-catenin (31) and p130 cas (32). The results described above suggest that PTP1B may be a participant in several signaling pathways. Thus, it is highly desirable to obtain specific and potent PTP1B inhibitors to further elucidate its roles in various signaling pathways and to develop PTP1B-based therapeutics. We have recently acquired Compound 2 (Fig. 1) , the most potent (K i ϭ 2.4 nM) and selective PTP1B inhibitor identified to date, which exhibits several orders of magnitude selectivity in favor of PTP1B against a panel of PTPs (13) . Although Compound 2 contains several negative charges, which may prevent its direct usage in cellbased assays, we have prepared several cell-permeable analogs that are highly effective in inhibiting PTP1B in several cell lines. 2 The goal of the present study was to probe in detail the interactions between PTP1B and Compound 2 by a combination of kinetics, mass spectrometry, and site-directed mutagenesis experiments. The results have led to an increased understanding of the molecular basis for potent and specific PTP1B inhibition. This understanding is essential for the further development of more potent and selective PTP1B inhibitors and for the design of specific inhibitors tailored to other members of the PTP family.
The Binding Mode of Compound 2 to PTP1B-As shown in Fig. 1, Compound 2 is a nonhydrolyzable derivative of Compound 1, in which the two phosphate moieties are replaced with two difluorophosphonate groups. Compound 1 was the most potent ligand for PTP1B/C215S identified from a library that contains two linked motifs, one targeted to the pTyr-binding catalytic site, and the other to a unique adjacent noncatalytic site in PTP1B (13) . Although pTyr is the canonical ligand for PTP active site, a priori, both pTyr/phosphonodifluoromethyl phenylalanine and 4-phosphophenylacetic acid/4-phosphonodifluoromethyl phenylacetic acid could potentially engage in interactions with the PTP1B active site. To differentiate between these two possibilities, we prepared Compounds 3 and 4 ( Fig.  1) , each of which contains only one hydrolysable phosphate group (Fig. 1) . We next evaluated whether 3 and 4 could serve as PTP1B substrates by continuously monitoring the increase in absorbance at 282 nm (16) . No reaction was observed when Compound 3 (100 M) was incubated with PTP1B at concentrations up to 1.8 M (Fig. 2A) . In addition, we did not detect any hydrolysis when the reaction was analyzed by an inorganic phosphate assay (15) . Thus Compound 3 is not a substrate for PTP1B. Instead, it acts as a reversible and competitive inhibitor for the PTP1B-catalyzed hydrolysis of pNPP with a K i of 28 Ϯ 1 nM. In contrast, robust dephosphorylation was observed when Compound 4 was mixed with PTP1B (Fig. 2B) . Kinetic analysis showed that the k cat and K m for the PTP1B-catalyzed hydrolysis of Compound 4 were 59.0 Ϯ 0.5 s Ϫ1 and 3.4 Ϯ 0.2 M, respectively. These values place 4 as one of the most efficient substrates for PTP1B ever reported (10) . Furthermore, the dephosphorylated form of Compound 4 exhibits no inhibition of the PTP1B-catalyzed reaction at 10 M. Collectively, the results suggest that pTyr/phosphonodifluoromethyl phenylalanine occupies the active site of PTP1B whereas 4-phosphophenylacetic acid/4-phosphonodifluoromethyl phenylacetic acid potentially interacts with a secondary site in the vicinity of the active site.
Localization of Compound 2 Binding Sites in PTP1B-To map out the interaction surface between PTP1B and Compound 2, the effect of Compound 2 on the rate of H/D exchange of the backbone amides in PTP1B was measured using electrospray ionization-mass spectrometry (see "Experimental Procedures" for details). H/D exchange, combined with mass spectrometric and proteolytic mapping, permits segment-specific identification of solvent-accessible exchange sites in proteins. This technique has been applied to localize protein-protein interaction surfaces and mapping ligand binding sites in a number of systems (17, (33) (34) (35) . The basic idea for this approach is that ligand binding or protein-protein interaction perturbs solvent proton accessibility and thus the rate of H/D exchange properties of contact regions of the proteins. The binding interface can be localized by comparing the rate of H/D exchange on proteins in bound and unbound states. Changes in deuterium incorporation within specific regions of proteins can be detected by peptidic digestion of the deuterium-labeled proteins, followed by HPLC separation and mass spectrometric analysis. Fig. 3 shows the global H/D exchange of PTP1B in the presence or absence of Compound 2. Up to 183 (of a possible 298) backbone amide hydrogens can exchange with deuterium in PTP1B within the first 40 min of the reaction. Compared with PTP1B alone, about 22 amide protons were protected from exchange in the PTP1B⅐2 complex, indicating that H/D exchange was affected as a result of ligand binding. To identify the protected regions in PTP1B, we subjected the deuterated PTP1B to limited pepsin digestion, followed by HPLC separation of the resulting peptides, and ESI-MS determination of deuterium incorporation into each of the individual peptides. Overall, 31 peptide segments, covering 85% of the PTP1B amino acid sequence, were identified as shown in Fig. 4 (Fig. 5) .
To visualize more directly the H/D exchange results, we represent changes in H/D exchanges for the PTP1B⅐2 complex versus PTP1B alone by color-coding segments of the known structure of PTP1B bound with pTyr (12) . As shown in Fig. 6 A) and 4 (B) . All of the kinetic measurements were performed at pH 7.0 in 50 mM 3,3-dimethylglutarate buffer, 1 mM EDTA, 1 mM dithiothreitol, ionic strength of 0.15 M adjusted by addition of NaCl, and 30°C.
FIG. 3. Global H/D exchange for PTP1B (q) and PTP1B plus Compound 2 (E).
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loop (residues 36 -57), the ␤11-␣3 loop (residues 176 -187, also known as the WpD loop), and the ␣5-␣6 loop (residues 254 -264), which may contribute to ligand binding affinity and specificity. It is interesting to note that within these peptide segments that display reduced H/D exchange when Compound 2 is bound to PTP1B, residues Tyr 46 , Arg 47 , and Asp 48 in the ␣1-␤1 loop and Phe 182 in the WpD loop have been shown to be involved in binding of pTyr-containing peptide substrates (8, 10, 14) . Residues Arg 24 , Arg 254 , Met 258 , Gly 259 , and Gln 262 define the second aryl phosphate binding site in PTP1B (12) . Although the H/D exchange, coupled with the mass spectrometry method, is very efficient in identifying areas in the protein that are affected by ligand binding, it usually does not provide residue-specific resolution for amino acids directly involved in ligand binding, and it cannot differentiate changes due to direct binding from those due to conformational or dynamic changes. To identify the residues that are in direct contact with Compound 2, we introduced amino acid substitutions into PTP1B by site-directed mutagenesis and analyzed the resulting effects on the binding affinity of Compound 2 for PTP1B as described below.
Effect of Mutations in PTP1B on pNPP Hydrolysis-The residues were selected based on results from the H/D exchange experiments and their locations in the three-dimensional structure of PTP1B. The wild-type and mutant PTP1Bs were expressed in E. coli and purified to near homogeneity as judged by SDS-PAGE. As a control, we evaluated the effects of amino acid substitutions in PTP1B using pNPP as a substrate. All kinetic measurements were performed at 30°C in pH 7.0, 50 mM 3,3-dimethylglutarate buffer, containing 1 mM EDTA and with an ionic strength of 0.15 M. As can be seen from Table I , with the exception of Y46A, F182A, R254A, R257A, and Q262A, no significant differences in the kinetic parameters (k cat and K m ) for pNPP hydrolysis were observed for the wild-type and mutant PTP1Bs.
Tyr 46 is part of the PTP1B active site (the canonical pTyr binding site) and is engaged in hydrophobic packing with pTyr in the substrate (8) . Phe 182 resides in the WpD loop, and it also forms hydrophobic stacking with pTyr in the substrate. Kinetic studies indicate that the interaction between the side chain of Phe 182 and pTyr in the substrate may be important for precise positioning of the general acid/base Asp 181 in the WpD loop for effective catalysis (14) . The observed effects for Y46A and F182A are essentially the same as those reported in an earlier study (14) . Arg 254 and Arg 257 seem to play a structural role in maintaining the active site architecture. Arg 254 is surface-exposed and participate in an H-bond array to stabilize the active site phosphate-binding loop (P-loop; residues 216 -222), whereas Arg 257 is buried and H-bonds to the carbonyls of residues in the P-loop. The magnitudes of decrease in k cat and k cat /K m for R254A and R257A are similar to those observed for mutants of the equivalent residues (R437A and R440A) in the Yersinia PTP (36) . The side chain of Gln 262 is close to the active site and defines a portion of the rim for the pTyr binding pocket (8) . Previous work on Gln 262 (14, 37) and the structural equivalent Gln 446 in the Yersinia PTP (38) suggest that the side chain of Gln 262 works together with Asp 181 to position and activate the nucleophilic water for phosphoenzyme hydrolysis. In short, the effect of the Gln 262 to Ala mutation determined in this study agrees well with earlier measurements (14) .
Effect of Mutations in PTP1B on Vanadate Binding-As a second control, we evaluated the effect of amino acid substitutions in PTP1B by measuring the K i values for the oxyanion vanadate. Vanadate is a reversible and competitive inhibitor of PTP1B (14, 39) , which may resemble to some extent the transition state of the hydrolysis of the phosphoenzyme intermediate (40) . The vanadate moiety in the PTP1B complex is trigonal bipyramidal, with three short equatorial nonbridging V-O bonds, one apical bridging V-O bond, and one long V-S bond to Cys 215 (37) . The three equatorial V-O bonds are hydrogenbonded with two of the Arg 221 side chain N-Hs, as well as several backbone N-Hs of the P-loop. The conserved Asp 181 and Gln 262 each makes a hydrogen bond with the apical oxygen of vanadate, consistent with their proposed roles in catalysis as discussed above. Similar to that observed for the wild-type PTP1B, vanadate competitively inhibited all mutant forms of PTP1B. As summarized in Table I , the K i values of vanadate for most of the mutant PTP1Bs are similar to that for the wild-type enzyme. The exceptions are again Y46A, F182A, R254A, R257A, and Q262A, which have reduced affinity for vanadate compared with the wild-type PTP1B. Given the importance of these residues in either catalysis or maintaining the active site structure, it is understandable that mutations in these positions would affect vanadate binding. Because the P-loop contributes several hydrogen bonds (N-Hs from the backbone and the side chain of Arg 221 ) to bind vanadate, much larger decreases in binding affinity were observed when Arg 254 or Arg 257 were replaced with an Ala. Interestingly, both catalysis and oxyanion binding could be partially restored with Lys substitutions at these positions (Table I) . Similar results were observed with the equivalent residues in the Yersinia PTP (36) .
Effect of Mutations in PTP1B on Inhibition by Compound 2-Having characterized all of the mutants with pNPP and vanadate, we proceeded to determine whether any of the mutations affect the ability of PTP1B to bind Compound 2. As observed with wild-type PTP1B (13), Compound 2 inhibited the reaction catalyzed by mutant PTP1Bs reversibly and competitively with respect to the substrate. For comparison, the K i values of 2 for PTP1B and the mutants are included in Table I . Structural studies have shown that the three terminal oxygens in pTyr are primarily stabilized by the guanidinium group of Arg 221 and the main chain nitrogens of the P-loop. As expected, the ability of PTP1B to bind Compound 2 was severely compromised (by 3 orders of magnitude) when the side chains of Arg 254 and Arg 257 were removed, which likely disrupt the structure of the P-loop. 24 by an Ala did not lead to any changes in the kinetic parameters of pNPP hydrolysis and in the inhibition constant of vanadate (Table I) , indicating no structural perturbations in the active site. No change in binding affinity for Compound 2 was observed for R24A, indicating that the 4-phosphonodifluoromethyl phenylacetic acid moiety in 2 does not interact with Arg 24 . We next examined residues Met 258 and Gly 259 . A recent study showed that when Gly 259 in PTP1B was changed to the corresponding bulkier Gln residue in PTP␣, a 180-fold decrease in affinity was observed for a PTP1B inhibitor designed to address the region around residues 258 and 259 (41) . As shown in Table I , introduction of the corresponding residues in PTP␣ into PTP1B (generating M258C and G259Q, respectively) has very modest effects (2-4-fold) on ligand binding affinity. Because the increases in K i of Compound 2 for M258C and G259Q are of the same magnitudes in increases in K i of vanadate, it is unlikely that the 4-phosphonodifluoromethyl phenylacetic acid moiety makes direct contacts with residues 258 and 259. The observed effects on M258C and G259Q are most likely indirect as a result of structural perturbations to the active site or conformation of Gln 262 (see Table I 
